Loading...
Loading...
PTIX| Name | Value |
|---|---|
| Revenues | 3.2K |
| Cost of Revenue | 26.6K |
| Gross Profit | -23.4K |
| Operating Expense | 1,185.6K |
| Operating I/L | -1,212.2K |
| Other Income/Expense | -464.0K |
| Interest Income | 53.7K |
| Pretax | -1,676.2K |
| Income Tax Expense | 0.0K |
| Net Income/Loss | -1,676.2K |
Protagenic Therapeutics, Inc. is a biopharmaceutical company specializing in the discovery and development of therapeutics for stress-related neuropsychiatric and mood disorders. Their lead compound, PT00114, is a synthetic form of teneurin carboxy-terminal associated peptide, designed to dampen overactive stress responses in the brain. The company generates revenue through the research, development, and potential commercialization of these innovative therapeutics.
